Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1

Anastasia Zekeridou; Binxia Yang; Vanda A. Lennon; Yong Guo; Liang Wu; Claudia F. Lucchinetti; Andrew McKeon; Sean J. Pittock; Eoin P. Flanagan

doi:10.1002/ana.26320

Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1

Anastasia Zekeridou, Binxia Yang, Vanda A. Lennon, Yong Guo, Liang Wu, Claudia F. Lucchinetti, Andrew McKeon, Sean J. Pittock, Eoin P. Flanagan

Research output: Contribution to journal › Article › peer-review

Abstract

The antigen specificity of Anti-Neuronal Nuclear Antibody-type 3 (ANNA3)-IgG is unknown. We identified Dachshund-homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen-specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1-IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675.

Original language	English (US)
Pages (from-to)	670-675
Number of pages	6
Journal	Annals of neurology
Volume	91
Issue number	5
DOIs	https://doi.org/10.1002/ana.26320
State	Published - May 2022

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.26320

Cite this

@article{ae2d4a8dc9324c848b97e3fe94c91dd7,

title = "Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1",

abstract = "The antigen specificity of Anti-Neuronal Nuclear Antibody-type 3 (ANNA3)-IgG is unknown. We identified Dachshund-homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen-specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1-IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675.",

author = "Anastasia Zekeridou and Binxia Yang and Lennon, {Vanda A.} and Yong Guo and Liang Wu and Lucchinetti, {Claudia F.} and Andrew McKeon and Pittock, {Sean J.} and Flanagan, {Eoin P.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Neurological Association.",

year = "2022",

month = may,

doi = "10.1002/ana.26320",

language = "English (US)",

volume = "91",

pages = "670--675",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1

AU - Zekeridou, Anastasia

AU - Yang, Binxia

AU - Lennon, Vanda A.

AU - Guo, Yong

AU - Wu, Liang

AU - Lucchinetti, Claudia F.

AU - McKeon, Andrew

AU - Pittock, Sean J.

AU - Flanagan, Eoin P.

PY - 2022/5

Y1 - 2022/5

N2 - The antigen specificity of Anti-Neuronal Nuclear Antibody-type 3 (ANNA3)-IgG is unknown. We identified Dachshund-homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen-specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1-IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675.

AB - The antigen specificity of Anti-Neuronal Nuclear Antibody-type 3 (ANNA3)-IgG is unknown. We identified Dachshund-homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen-specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1-IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675.

UR - http://www.scopus.com/inward/record.url?scp=85125538325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125538325&partnerID=8YFLogxK

U2 - 10.1002/ana.26320

DO - 10.1002/ana.26320

M3 - Article

C2 - 35150165

AN - SCOPUS:85125538325

SN - 0364-5134

VL - 91

SP - 670

EP - 675

JO - Annals of neurology

JF - Annals of neurology

IS - 5

ER -

Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this